Breast Cancer

HER-2 overexpression in breast cancer is a marker for treatment resistance and orchestrates distinct tumour biology. Our group developed novel, very stable linkers for labeling trastazumab with 64Cu for in vivo imaging of HER-2 breast tumours. In a separate, but related study, the metabolic activity and hypoxic status of HER-2 breast tumours was also examined.